

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 August 2024 (08.08.2024)



(10) International Publication Number
WO 2024/160822 A1

(51) International Patent Classification:

C07D 498/14 (2006.01) A61P 43/00 (2006.01)
C07D 498/18 (2006.01)

(21) International Application Number:

PCT/EP2024/052241

(22) International Filing Date:

30 January 2024 (30.01.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/442,247 31 January 2023 (31.01.2023) US

(71) Applicant: **JAZZ PHARMACEUTICALS IRELAND LIMITED** [IE/IE]; Waterloo Exchange, Waterloo Road, Dublin, 4 (IE).

(72) Inventors; and

(71) Applicants: **CHOVATIA, Prafulkumar** [GB/GB]; c/o Evotec (UK) Limited, 114 Innovation Drive, Milton Park, Abingdon Oxfordshire OX14 4RZ (GB). **OUVRY, Gilles** [FR/GB]; c/o Evotec (UK) Limited, 114 Innovation Drive, Milton Park, Abingdon Oxfordshire OX14 4RZ (GB). **MODICOM, Florian** [FR/GB]; c/o Evotec (UK) Limited, 114 Innovation Drive, Milton Park, Abingdon Oxfordshire OX14 4RZ (GB). **CAIN, Ricky Michael** [GB/GB]; c/o Evotec (UK) Limited, 114 Innovation Drive, Milton Park, Abingdon Oxfordshire OX14 4RZ (GB). **FIORUCI, Diego** [IT/IT]; c/o Aptuit (Verona) Srl, Via A. Fleming 4, 37135 Verona (IT). **MARINELLI, Davide** [IT/IT]; c/o Aptuit (Verona) Srl, Via A. Fleming 4, Verona 37135 (IT). **LESLIE, Colin Philip** [GB/IT]; c/o Aptuit (Verona) Srl, Via A. Fleming 4, 37135 Verona (IT). **PIZZI, Domenica Antonia** [IT/IT]; c/o Aptuit (Verona) Srl, Via A. Fleming 4, 37135 Verona (IT). **ZANFORLIN, Enrico** [IT/IT]; c/o Aptuit (Verona) Srl, Via A. Fleming 4, 37135 Verona (IT).


MERLINI, Valentina [IT/IT]; c/o Aptuit (Verona) Srl, Via A. Fleming 4, 37135 Verona (IT). **PIZZOLATO, Stefano** [IT/IT]; c/o Aptuit (Verona) Srl, Via A. Fleming 4, 37135 Verona (IT). **DI GUGLIELMO, Bruno** [IT/IT]; c/o Aptuit (Verona) Srl, Via A. Fleming 4, 37135 Verona (IT). **DEL-MONTE, Marco** [IT/IT]; c/o Aptuit (Verona) Srl, Via A. Fleming 4, 37135 Verona (IT). **CARNEVALE, Gennaro** [IT/IT]; c/o Aptuit (Verona) Srl, Via A. Fleming 4, 37135 Verona (IT). **DI FRUSCIA, Paolo** [IT/GB]; c/o Jazz Pharmaceuticals Research UK Ltd, Building 730, Kent Science Park, Sittingbourne Kent ME9 8AG (GB).

(74) Agent: **COOLEY (UK) LLP**; 22 Bishopsgate, London Greater London EC2N 4BQ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOF



(57) Abstract: Provided herein are compounds of Formula (I), (I), or pharmaceutically acceptable salt thereof, wherein m, n, p, L, R¹, R², R³, R⁴, R⁵, R⁶, Formula (AA), (AA), V, X, Y and Z are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, e.g., in the treatment of a disease or disorder that is treatable by administration of an Orexin agonist.

[Continued on next page]

Published:

— with international search report (Art. 21(3))